News

Published on 21 Nov 2023 on GuruFocus.com via Yahoo Finance

Insider Sell Alert: BridgeBio Pharma Inc's Brian Stephenson Unloads 22,685 Shares

Article preview image

In a notable insider transaction, Brian Stephenson, the Secretary, Treasurer & CFO of BridgeBio Pharma Inc (NASDAQ:BBIO), sold 22,685 shares of the company on November 17, 2023. This move has caught the attention of investors and market analysts, as insider selling patterns can provide valuable insights into a company's financial health and future prospects.

Who is Brian Stephenson of BridgeBio Pharma Inc?

Warning! GuruFocus has detected 5 Warning Signs with BBIO.

Read the rest of the article
NASDAQ.BBIO price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on...

The approval came ahead of the targeted action date of Nov. 29. Per... Plunges on Study Failure...

Zacks · via Yahoo Finance 29 Nov 2024
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults wit...

Zacks · via Yahoo Finance 26 Nov 2024
BridgeBio shares surge 25% on FDA approval of Attruby By Investing.com

BridgeBio Pharma, Inc. (NASDAQ:BBIO) received U.S. Food and Drug Administration (FDA) approval fo...

Investing.com 25 Nov 2024
BridgeBio Pharma Inc receives Investment Bank Analyst Rating Update By...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks...

Investing.com 25 Nov 2024
BridgeBio Soars After Drug Gets Nod in Rare Heart Condition

(Bloomberg) -- BridgeBio Pharma Inc. jumped the most in 16 months after its drug got US regulator...

Bloomberg · via Yahoo Finance 25 Nov 2024
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge...

On Friday, the FDA approved BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) Attruby (acoramidis), an...

Benzinga · via Yahoo Finance 25 Nov 2024
Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, w...

Insider Monkey · via Yahoo Finance 21 Nov 2024
BridgeBio Pharma CFO Brian Stephenson sells shares worth $93,136 By...

PALO ALTO, CA—Brian C. Stephenson, the Chief Financial Officer of BridgeBio Pharma, Inc....

Investing.com 20 Nov 2024
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa...

On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM...

Benzinga · via Yahoo Finance 19 Nov 2024
The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell...

One thing we could say about the analysts on BridgeBio Pharma, Inc. (NASDAQ:BBIO) - they aren't...

Simply Wall St. · via Yahoo Finance 18 Nov 2024

Copyright Statfolio @ 2024

Social Accounts